Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab-first versus FMT-first strategy for multiple recurrent Clostridioides difficile infection
NL-OMON52061Phase 4Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bezlotoxumab, fidaxomicin and vancomycin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Global cure of the treatment strategy. Planned start Nov 2021; status: withdrawn.
02
Drugs
bezlotoxumabfidaxomicinvancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NL-OMON52061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52061.